Primary Central Nervous System Lymphoma in Adults

A multidisciplinary team works together to provide you with personalized care for primary central nervous system lymphoma. This rare, fast-growing type of non-Hodgkin lymphoma can start in the brain, eyes, spinal cord, or meninges, which are the layers of tissue that cover and protect the brain and spinal cord. We use the newest genetic tests to determine what therapies are best for you. Your treatment plan may include chemotherapy, targeted drugs, and radiation therapy. You may also be eligible to participate in clinical trials, which offer access to promising new medications.

Clinical Trials and Research Studies

Phase 3

ACNS1931: A Phase 3 Study of Selumetinib (NSC# 748727 IND# 77782) or Selumetinib in Combination with Vinblastine for non-NF1 non-TSC Patients with Recurrent or Progressive Low-Grade Gliomas (LGGs) Lacking BRAFV600E or IDH1 Mutations

Learn More

Phase 6

A Phase II/III randomized study of R-miniCHOP with or without oral azacitidine (CC-486) in participants age 75 years or older with newly diagnosed diffuse large B cell lymphoma Grade IIIb Follicular Lymphoma transformed lymphoma and high-grade B-cell lymphomas with MYC and BCL2 and/or BCL6 rearrangements

Learn More

Phase 2

A Phase 2 Trial of the Combination of Polatuzumab Vedotin Venetoclax and Rituximab and Hyaluronidase Human for Relapsed and Refractory Mantle Cell Lymphoma

Learn More

Phase 2

DAY101-001/PNOC026/FIREFLY-1: A Phase 2 Open-Label Multicenter Study to Evaluate the Safety and Efficacy of the Oral Pan-RAF Inhibitor DAY101 in Pediatric Patients with BRAF-Altered Recurrent or Progressive Low-Grade Glioma

Learn More